Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours

Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving “First Patient First Visit[1]” in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers.